LQT-1213

LQT-1213 is a novel, first-in-class small molecule inhibitor of serum glucocorticoid regulated kinase 1 (SGK1), developed by Thryv Therapeutics for the treatment of Long QT Syndrome (LQTS). SGK1 plays a role in cardiac repolarization and its inhibition by LQT-1213 aims to shorten the prolonged QT interval characteristic of LQTS, thereby reducing the risk of life-threatening arrhythmias. The drug has demonstrated statistically significant and clinically meaningful reductions in QTcF (corrected QT interval) in both dofetilide-induced and congenital forms of long QT syndrome during early clinical trials. It has received Orphan Drug Designation from the FDA for this indication. Clinical studies have shown that LQT-1213 is generally well tolerated with no serious adverse events or over-shortening of the QTc interval reported[1][2][5][6][7].

Other names

THRV-NCETHRV NCE